Attached files
file | filename |
---|---|
8-K - PRIMARY DOCUMENT - Q BioMed Inc. | a8-kqbioconversionagreeme.htm |
Q BioMed Announces Full Settlement of All Convertible
Debt
Company Closes Financial Year End With No Outstanding Convertible
or Loan Debt
NEW YORK, December 5, 2017 — Q BioMed Inc. (OTCQB: QBIO), a
biotechnology acceleration Company, announced today that all
convertible notes and loans have been settled in full, including
the $4 million of convertible notes that had been issued pursuant
to a Securities Purchase Agreement dated November 29, 2016. The
company ended its 2017 financial year with no outstanding loans or
convertible debt.
Denis Corin, CEO of Q BioMed
Inc. said, “We are very pleased to end the fiscal year with a
strong balance sheet and with a solid capital and financial
structure from which to continue to build our
business.”
More information relating to the settlement of these debts can be
found in our Form 8-K filed today with the U.S. Securities and
Exchange Commission.
Forward-Looking Statements:
This press release may contain “forward-looking
statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development
programs and any other statements that are not historical facts.
Forward-looking statements are based on management’s current
expectations and are subject to risks and uncertainties that could
negatively affect our business, operating results, financial
condition and stock price. Factors that could cause actual results
to differ materially from those currently anticipated are: risks
related to our growth strategy; risks relating to the results of
research and development activities; our ability to obtain, perform
under and maintain financing and strategic agreements and
relationships; uncertainties relating to preclinical and clinical
testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of
products under development; our need for substantial additional
funds; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings. We expressly disclaim any obligation or undertaking to
release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our
expectations or any changes in events, conditions or circumstances
on which any such statement is based, except as required by
law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Source: Q BioMed Inc.